We’re the market leader in medical diagnostics and we intend to maintain this position. In the short to medium term, we’re managing the business through life cycle management. This means extending the life of our products by conducting new clinical trials and obtaining new indications for key products. Our heart diagnostic, Myoview™, has recently been approved for breast tumour imaging, and a new study of our X-ray product,Visipaque™, shows that it provides increased renal safety for at-risk patients.

In the longer term, we’re focusing on the development of molecular diagnostics, which are able to detect cellular changes that are the first signs of disease. We’re also working with GE Medical Systems to develop synthesis systems for producing proprietary PET (positron-emissiontomography) radiopharmaceuticals of consistently high quality.

A most exciting initiative is the Imanet™ network of research centres, where we partner with pharmaceutical companies such as Pfizer. It’s a win-win situation. Using our advanced imaging technologies to show the effect of new compounds on cells in the body, we help companies test potential new drugs and speed up their drug development. And, importantly, we gain access to new molecules that provide important leads for new molecular diagnostic products, fuelling our future flow of new products.